Aurisco announced that it recently received a Drug GMP Compliance Inspection Notification issued by the Zhejiang Medical Products Administration, confirming that its eplerenone active pharmaceutical ingredient production line meets the requirements of Good Manufacturing Practice for Drugs. The inspection took place from May 13 to May 15, 2026, covering Workshop 804 and the EPLC production line. Eplerenone tablets are mainly used to treat heart failure and hypertension, with hospital-end sales of 1.77 million yuan in 2025. Passing the inspection helps the company maintain product quality and production capacity. In the first quarter of 2026, Aurisco achieved revenue of 389 million yuan and net profit attributable to the parent company of 63.93 million yuan.
Aurisco Pharmaceutical Co LtdGMP compliance inspection passed for eplerenone API production line, ensuring regulatory approval and quality standards.